Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Resources
  • Knowledge Base
  • RadiometricSection
  • Data Analysis for Sulfur-35 GTP Binding Assays
Radiometric

Data Analysis for Sulfur-35 GTP Binding Assays

Section
Sulfur-35 GTP Binding Assays
Acetylation Assays Using Acetyl CoA
CAT Reporter Gene Assays
Cell and Metabolic Labeling
Chromium-51 Release Assay
DNA and RNA Labeling
Glucose Uptake Assays
In Vitro Kinase Assays
Iodine-125 Labeling of Proteins
Liquid Scintillation Counting
Phosphorus-32 Cell Labeling Assays
Phosphorylation Assays
Radiochemical Calculations
Radioimmunoassays
Radiometric Assays and Detection
Radiometric Ligand-Binding Assays
Scintillation Proximity Assays
Sulfur-35 GTP Binding Assays
Sulfur-35 Methionine Labeling
Thymidine Uptake Assays
Which Formulation Should I Choose?
Sub Section
Data Analysis for Sulfur-35 GTP Binding Assays
Data Analysis for Sulfur-35 GTP Binding Assays
GTP Filterplate Assay
SPA Assays for GTP Binding

Raw data

GTP binding data can be depicted in different ways. One option is to show your raw data, plotting counts per minute (cpm) versus ligand or compound concentration.

data-analysis-for-35s-gtp-binding-assays-fig1

Figure 1. Raw data for GTP binding to human adenosine A1 receptor membrane (#ES-010-M). Data was collected in SPA format, using WGA SPA PVT scintillation beads.

Stimulation over basal

Traditionally, GTP binding data is expressed as percentage signal over basal, or fold over basal. This means you are comparing the signal of your unstimulated receptor to the signal of the stimulated receptor. You should subtract the background (non-specific binding) when processing your data.

data-analysis-for-35s-gtp-binding-assays-fig2
data-analysis-for-35s-gtp-binding-assays-fig3

Figure 2. Equations for determining % signal over basal or fold-over-basal.


If you are calculating % signal over basal or fold-over-basal, you will need to run the following controls to use in the above equation:

  • Basal sample: cell membrane, buffer, an 35S-gamma-GTP (no agonist or antagonist)
  • Non-specific binding control: cell membrane, buffer, unlabeled GTP-gamma-S, and 35S-gamma-GTP. Excess unlabeled GTP-gamma-S is added prior to the addition of radiolabeled GTP-gamma-S. 

Potency (EC50 or IC50)

Potency is a measure of the concentration of a drug required to generate a particular response. Potency is generally indicated as the EC50 or IC50 of a given ligand or compound for your receptor (the concentration which gives half-maximal response).

Efficacy (Emax)

Efficacy is a measure of the maximum response generated by one ligand in comparison to the maximal response generated by a different ligand. It is a way of normalizing your data. Efficacy is most commonly used to compare the maximal response of agonists to one another.

For research use only. Not for use in diagnostic procedures. 

The information provided above is solely for informational and research purposes only. Revvity assumes no liability or responsibility for any injuries, losses, or damages resulting from the use or misuse of the provided information, and Revvity assumes no liability for any outcomes resulting from the use or misuse of any recommendations. The information is provided on an "as is" basis without warranties of any kind. Users are responsible for determining the suitability of any recommendations for the user’s particular research. Any recommendations provided by Revvity should not be considered a substitute for a user’s own professional judgment. 

ON THIS PAGE
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.